[IL-2 gene therapy in ENT carcinomas].
Suppressed cellular immunity is common in patients with squamous cell carcinoma of the head and neck (HNSCC). It was demonstrated in previous studies that administration of interleukin 2 (IL-2) results in enhanced antitumoral immunity in vitro as well as in vivo. Since the serum half-life of IL-2 is relatively short, repeated applications are necessary to achieve therapeutically effective serum concentrations, but this strategy might cause severe side effects. Therefore, methods that provide high local cytokine levels over a prolonged period of time without the need for repeated injections are desirable. Gene therapy as an innovative treatment approach using tumor cells stably transduced to produce IL-2 might meet these criteria. In vitro manipulated tumor cells, if readministered in the vicinity of non-manipulated tumor cells, may enhance a specific anti-tumor response in vivo without systemic side effects. The present manuscript reviews the current literature dealing with IL-2-protein and -gene therapy with special emphasis on head and neck cancer. Our own in vitro results with IL-2 gene therapy in conjunction with published data from other authors argue in favour of an in vivo approach for this therapeutic strategy that is currently in progress in our department.
Lang
S
S
Klinik und Poliklinik für Hals-, Nasen- und Ohrenkranke der Ludwig-Maximilians-Universität München, Klinikum Grosshadem.
Zeidler
R
R
Pauli
C
C
Andratschke
M
M
Wollenberg
B
B
D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D015316:Genetic Therapy; D006801:Humans; D007376:Interleukin-2 / Q000235:genetics*; D010039:Otorhinolaryngologic Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D016896:Treatment Outcome
D007376:Interleukin-2